Abdelrahman H. Daifalla: Think Like the Embryo

Abdelrahman H. Daifalla, Medical Director and Consultant IVF/ICSI at Queens Medical Center and Consultant of IVF and Reproductive Medicine at Gannah IVF Hospital, shared on LinkedIn:

“In IVF, we spend enormous effort asking whether an embryo is good enough to transfer.

But perhaps we should ask another question with equal seriousness: Is the patient truly ready to receive that embryo? My latest article explores the idea behind Think Like the Embryo and why the pre-transfer decision deserves a more structured clinical approach.

Think Like the Embryo, the Pre-Transfer Decision in IVF

Prediction asks how likely pregnancy is. Readiness asks whether anything should be optimized first. They are not the same question – and in IVF we invest far more effort in the first than in the second.

A patient can have a low predicted probability of pregnancy and still be entirely ready for embryo transfer.

Another can have an apparently favorable prognosis and still carry one specific, modifiable problem that reasonably changes the timing or the strategy.

Both statements can be true at the same time.

In IVF, we spend enormous effort asking whether an embryo is good enough to transfer.

We assess morphology. We evaluate development. We consider ploidy when indicated. We optimize laboratory conditions. We refine transfer technique.

But there is another question that deserves equal attention:

Is the patient ready to receive that embryo?

This question sits at the heart of what I describe as Think Like the Embryo.

It is not a literal attempt to imagine an embryo making clinical decisions.

It is a way of changing the direction of our reasoning.

Instead of beginning with:

‘Do we have an embryo to transfer?’

we begin with:

‘If we transfer this embryo today, what biological and clinical environment are we asking it to enter?’

That small change in perspective may help us think more systematically about one of the most complex decisions in assisted reproduction.

The Embryo Is Only One Part of the Transfer Equation

Advances in embryology have transformed IVF.

Time-lapse imaging, improved culture systems, vitrification, blastocyst culture, genetic testing, and increasingly sophisticated embryo-assessment tools have allowed us to characterize embryo competence in ways that were impossible a generation ago.

This progress matters.

But even an apparently favorable embryo does not exist independently of the patient receiving it.

Implantation occurs within a biological system influenced by:

• uterine anatomy
• endometrial conditions
• endocrine and metabolic health
• previous treatment history
• transfer technique
• patient-specific clinical factors

This does not mean every possible abnormality should be investigated or treated before transfer.

The real challenge is different:

Identify what is clinically meaningful, modifiable, and supported by evidence.

Optimization should be targeted, not indiscriminate.

Think Like the Embryo: Four Questions Before Transfer

1. Is the uterine environment structurally appropriate?

Before implantation can occur, the embryo needs access to a uterine cavity capable of supporting pregnancy.

Some findings are widely accepted as worth addressing first – a hydrosalpinx communicating with the cavity, a submucous myoma distorting it, significant intrauterine adhesions. Others, such as a small intramural myoma with an undistorted cavity, rarely justify delaying transfer.

The objective is not routine invasive investigation for every patient.

The objective is to avoid proceeding when there is a meaningful anatomical problem that reasonably should be addressed first.

Optimization should be selective, not excessive.

2. Are there relevant systemic factors that remain uncontrolled?

Reproductive medicine does not occur in isolation from the rest of medicine.

Endocrine, metabolic, and systemic factors may influence:

• treatment planning
• pregnancy safety
• reproductive outcomes
• timing of embryo transfer

Overt thyroid dysfunction and poorly controlled diabetes are reasonable examples of findings worth correcting before proceeding. Many other results sit in a far less certain space, where the test is easy to order and the evidence for acting on it remains contested.

The purpose is not to create a theoretical ՛perfect IVF patient.՛

No such patient exists.

Instead, we should be able to state clearly which factors are:

• acceptable
• in need of monitoring
• worth optimizing before proceeding

This is fundamentally different from simply generating a longer checklist.

3. Have we learned enough from previous IVF attempts?

A previous unsuccessful transfer is not only a negative result.

It is also clinical information.

Questions worth asking include:

• Was the transfer technically difficult?
• Was embryo development different from previous cycles?
• Were there unexpected findings?
• Was endometrial preparation appropriate?
• Did anything change after the previous attempt?
• Is there something clinically meaningful we now understand better?

The temptation after IVF failure is often to order more tests.

But sometimes the better first step is to reconstruct the previous cycle carefully.

Clinical intelligence begins with understanding what has already happened, before ordering what comes next.

4. Is the transfer procedure itself optimized?

Embryo transfer may be the final technical step of IVF, but its execution still matters.

Evidence-based procedural principles such as accurate placement and atraumatic technique should remain central.

The key question becomes:

Can we deliver the embryo under the best reasonable clinical conditions?

The best embryo and the best-prepared patient can still be undermined by a poorly executed transfer.

Readiness Is Not the Same as Prediction

This distinction deserves to be stated precisely.

A predictive model asks:

՛What is the probability of pregnancy or live birth?՛

A readiness framework asks:

՛Is there a clinically relevant reason to optimize something before proceeding?՛

These are not the same question, and they do not always point in the same direction. That is why the two patients described at the beginning of this article are not a contradiction.

Readiness should therefore not become another way of classifying patients as ՛good՛ or ՛bad.՛

Its purpose is to separate:

What can be changed from what cannot.

That distinction matters clinically and ethically.

The Risk of Over-Optimization

This philosophy also carries an important warning.

If ՛optimize before transfer՛ is interpreted too broadly, it can easily turn into overtesting.

Modern fertility care already contains many investigations and add-on treatments whose clinical value remains uncertain.

The correct question is not:

՛What else can we test?՛

It is:

՛Would the result of this test meaningfully change management?՛

If the answer is no, the test may add information without adding intelligence.

From More Data to Better Decisions

IVF is becoming increasingly data-rich.

We now have clinical data, hormonal data, ultrasound data, embryology data, genetic data, laboratory data, and algorithm-generated information.

Artificial intelligence will add even more.

But the future challenge in reproductive medicine may not be obtaining more data.

It may be:

Integrating existing data into clinically meaningful decisions.

The clinician should still be able to answer:

• Why are we proceeding?
• Why are we delaying?
• What are we optimizing?
• What evidence supports that decision?
• What remains uncertain?
• What does the patient need to understand?

An intelligent clinical system should make these answers clearer, not more opaque.

Think Like the Embryo Is Ultimately About the Patient

The phrase focuses attention on the embryo, but its deeper purpose is patient-centered.

Every additional test, delay, procedure, and intervention has consequences.

Patients experience time, cost, anxiety, and uncertainty.

Therefore, optimization must always remain proportionate.

Sometimes the right decision will be:

Optimize first.

Sometimes it will be:

Proceed now.

And sometimes the most scientifically responsible answer will be:

There is not enough evidence to justify doing anything differently.

That third answer is just as important as the first two.

A Framework That Must Be Tested

This philosophy has influenced the development of DISS IVF – Daifalla IVF Success System, a clinical intelligence framework focused on structured IVF assessment, readiness, optimization, and explainable decision support.

But the principle must come before the product.

A conceptual framework is not automatically a validated clinical tool.

Any system that supports reproductive decision-making should ultimately demonstrate:

• reliability
• transparency
• clinical utility
• safety
• prospective validation
• meaningful outcome relevance

The objective should never be to replace clinical judgment with another score.

The objective is to make clinical judgment more structured, more explainable, and more evidence-aware.

Conclusion

IVF has become increasingly sophisticated in how it evaluates embryos.

The next step may be to become equally sophisticated in evaluating the decision to transfer.

Thinking like the embryo means widening the clinical lens:

Embryo + Patient + Environment + Timing + Transfer

Not every patient needs more intervention.

Not every abnormality requires correction.

Not every failed transfer requires another test.

But every embryo transfer deserves one careful question:

Are we proceeding because the patient is ready – or simply because an embryo is available?

That is the distinction behind Think Like the Embryo.

And it may be one of the most useful questions we can bring back to everyday IVF practice.”

Other articles featuring Abdelrahman H. Daifalla on Fertility News.